Australia and New Zealand PCR Systems Market Size Analysis - Market Share, Forecast Trends and Outlook Report (2025-2034)

Key Market Trends and Insights

• Based on techniques, real-time PCR is expected to lead with rapid, precise quantification capabilities.
• Diagnostic-based applications are expected to dominate due to rising demands for disease detection.
• Based on region, Australia led the market and accounted for over 80% of the revenue share in the historical period.

Market Size and Forecast

• CAGR (2025-2034): 8.40% 
• Largest Market in 2024: Australia

Australia and New Zealand PCR Systems Market Overview

PCR systems are essential tools in modern molecular diagnostics, widely used across clinical, research, and biotechnology settings for accurate genetic analysis. In Australia and New Zealand, the PCR systems market is witnessing consistent growth, fueled by increasing healthcare demands, infectious disease surveillance, and advancements in life sciences. Supportive government policies, rising investment in research, and the growing need for precise diagnostic tools are key factors driving adoption. Enhanced laboratory infrastructure and the integration of innovative PCR technologies are further contributing to the market's expanding role in regional healthcare.

Australia and New Zealand PCR Systems Market Growth Drivers

Rising Hepatitis C Treatment Rates to Enhance the Growth in the Australia and New Zealand Market

An increasing focus on hepatitis C treatment is driving the demand for advanced diagnostic tools, including PCR systems, across Australia and New Zealand. As of June 2024, the Burnet Institute reported that 68,890 individuals were living with hepatitis C in Australia, with a year-on-year rise in treatment uptake for the first time since 2016. This renewed treatment momentum necessitates accurate viral load monitoring, thereby supporting the expansion of the regional PCR systems market.

Australia and New Zealand PCR Systems Market Trends

Some of the trends in the market are increasing approval of advanced PCR systems and the global introduction of integrated PCR platforms.

Rising Approvals of Advanced PCR Systems are Likely to Accelerate Market Growth

The rising approval of advanced digital PCR technologies for clinical use is a growing trend in the PCR systems market in Australia and New Zealand. For instance, in November 2024, QIAGEN’s QIAcuityDx system was approved by the Australian Register of Therapeutic Goods (ARTG), expanding its application in oncology and infectious disease diagnostics. Such regulatory endorsements are enhancing diagnostic precision and accessibility and are likely to significantly accelerate market growth across the region.

Launch of Integrated PCR Platforms to Boost Australia and New Zealand PCR Market Demand

The introduction of advanced, integrated diagnostic technologies is an emerging development, influencing the market significantly. For instance, in July 2025, Seegene Inc. unveiled STAgora™ at ADLM 2025 in Chicago, an AI-powered infectious disease intelligence platform seamlessly integrated with CURECA™, the company’s fully automated, unmanned PCR system. Positioned as a launchpad for international collaboration, this innovation is expected to accelerate regional adoption and significantly contribute to market growth.

Australia and New Zealand PCR Systems Market Share

Real-Time PCR Technique Expected to Lead the Market by Technology

PCR is utilized through various advanced techniques, including conventional PCR, real-time PCR, digital PCR, reverse transcription PCR, hot-start PCR, multiplex PCR, and other specialized methods. Among these, real-time PCR is projected to lead the market due to its accuracy, rapid turnaround, and quantitative analysis. For instance, in March 2023, BGI Genomics’ Multiplex Real-time Fluorescent RT-PCR Kit gained approval in Australia for simultaneous detection of SARS-CoV-2 and Influenza A & B, highlighting its critical role in enhancing diagnostic precision and public health readiness across the region.

Australia and New Zealand PCR Systems Market Analysis by Region

The market is divided into regions such as Australia and New Zealand. Among these, Australia is expected to lead the market due to its strong presence of research institutions, well-established biotechnology sector, and rising government investments in molecular diagnostics. The country's robust healthcare spending and rapid adoption of advanced technologies further position it as the dominant force in the regional PCR systems market.

Leading Players in the Australia and New Zealand PCR Systems Market

The Australia and New Zealand PCR systems market research report by Expert Market Research provides an in-depth analysis of the competitive landscape, offering key insights into funding trends, investments, and strategic initiatives by major players. It tracks recent investments, mergers, acquisitions, and partnerships that showcase the market's growth trajectory. Additionally, the report details strategic activities by leading companies, including regional expansions, adoption of new technologies, and efforts to enhance capacity, helping stakeholders better understand the market dynamics and positions of key industry players. Some of the leading players are as follows:

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc., a leader in scientific solutions, is actively involved in the PCR systems market through its innovative diagnostics portfolio. In 2022, the company launched the CE-IVD-marked TaqPath respiratory viral select panel, which enables rapid detection of five common respirato ry viruses using advanced PCR technology. Designed for scalability and efficiency, this solution supports laboratories in expanding molecular testing capabilities without increasing operational costs.

F. Hoffmann-La Roche Ltd

F. Hoffmann-La Roche Ltd is a key player in the market. Its Digital LightCycler® system is a semi-automated digital PCR platform designed for precise nucleic acid quantification. Featuring advanced nanowell plate configurations and high-resolution detection, it  supports applications such as gene expression, copy number variation, and rare mutation detection, strengthening Roche’s role in advancing molecular diagnostics.

Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc., a leader in life science research and clinical diagnostics, continues to advance the PCR systems market with its launch of the ddPLEX ESR1 Mutation Detection Kit. Designed for the QX600 Droplet Digital PCR System, this ultrasensitive, multiplexed assay supports oncology research through  precise detection of ESR1 mutations. Bio-Rad’s innovative solutions significantly contribute to the region's growing demand for advanced PCR technologies in translational and clinical research.

Agilent Technologies, Inc.

Agilent Technologies, Inc. is a leading player in the global PCR systems market, offering a comprehensive portfolio of real-time PCR (qPCR) solutions. Its flagship AriaMx Real-Time PCR System integrates amplification, detection, and data analysis for high-performance applications. The company also provides  detection kits, master mixes, nucleic acid isolation kits, plastics, and starter packs, supporting diverse research and diagnostic needs in the PCR domain.

Other key players in the market include QIAGEN N.V., Abbott Laboratories, Danaher Corporation, bioMérieux SA, PerkinElmer, Inc., Fluidigm Corporation, Eppendorf AG, and Becton, Dickinson and Company (BD).

Key Questions Answered in the Australia and New Zealand PCR Systems Market Report

• What was the Australia and New Zealand PCR systems market value in 2024?
• What is the Australia and New Zealand PCR systems market forecast outlook for 2025-2034?
• What are the major factors aiding the Australia and New Zealand PCR systems market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major Australia and New Zealand PCR systems market trends?
• Which product is expected to dominate the market segment?
• Which technique is projected to lead the market segment?
• Which application is anticipated to drive the market segment?
• Which end user is likely to dominate the market segment?
• Who are the key players involved in the Australia and New Zealand PCR systems market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?